Skip to main content
logo
Bright Minds Biosciences Inc. (DRUG)
NASDAQ: DRUG · Real-Time Price · USD
72.81
-1.73 (-2.32%)
Aug 28, 2026, 4:00 PM EDT - Market closed

Bright Minds Biosciences Cash Flow Statement

Millions CAD. Fiscal year is Oct - Sep.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Sep '25 Sep '24 Sep '23 Sep '22 Sep '21
Net Income
-24.51-12.23-2.8-7.37-14.96-8.65
Depreciation & Amortization
0.080.080.070.070.01-
Asset Writedown & Restructuring Costs
----0-
Stock-Based Compensation
5.113.180.841.150.90.88
Other Operating Activities
-5.82-0.28-00.07-0.260.14
Change in Accounts Payable
1.951.690.24-1.20.770.51
Change in Other Net Operating Assets
-1.47-1.13-0.20.26-0.04-0.2
Operating Cash Flow
-24.67-8.69-1.85-7.02-13.59-7.32
Operating Cash Flow Growth
------

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Sep '25 Sep '24 Sep '23 Sep '22 Sep '21
Long-Term Debt Repaid
--0.1-0.09-0.09-0.01-
Net Debt Issued (Repaid)
-0.1-0.1-0.09-0.09-0.01-
Issuance of Common Stock
293.5686.030.91.47627.84
Other Financing Activities
-18.2-0.36-0.8-0.8-1.79
Financing Cash Flow
275.2685.570.812.195.226.06

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Sep '25 Sep '24 Sep '23 Sep '22 Sep '21
Foreign Exchange Rate Adjustments
5.850.310.01-0.050.260.22
Net Cash Flow
256.4477.19-1.03-4.88-8.1318.96

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Sep '25 Sep '24 Sep '23 Sep '22 Sep '21
Levered Free Cash Flow
-18.77-4.6-0.69-4.22-7.58-3.85
Unlevered Free Cash Flow
-18.74-4.58-0.69-4.22-7.58-3.85

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Sep '25 Sep '24 Sep '23 Sep '22 Sep '21
Change in Working Capital
0.480.550.04-0.940.720.31
SEC Filings: 10-K · 10-Q